Safety Shot Soars 11.58% on Nootropics, Sleep Aid Expansion

Safety Shot's stock surged 11.58% in pre-market trading on June 4, 2025, driven by the company's strategic expansion into the rapidly growing nootropics and sleep aid markets.

Safety Shot, renowned for its blood alcohol-reducing supplement Sure Shot, has announced its entry into the nootropics and sleep aid markets. This move leverages the company's expertise in rapid wellness solutions to develop products aimed at enhancing cognitive function and improving sleep quality. The initiative is built on the foundational principles of Sure Shot, which focuses on boosting clarity, energy, and mood.

The global nootropics market, currently valued at $6.5 billion, is projected to reach $14.9 billion by 2034, growing at a compound annual growth rate (CAGR) of 8.7%. Similarly, the sleep supplements market, valued at $6.8 billion, is expected to hit $11.8 billion by 2034, with a CAGR of 5.1%. These high-growth markets present significant opportunities for Safety Shot, which aims to create unique formulations that prioritize efficacy and tangible results.

Under the leadership of CEO Jarrett Boon and COO David Sandler, Safety Shot is poised to make a strategic pivot. The company is extending its "Feel Better Fast" brand promise into daily wellness applications, targeting two complementary wellness categories with substantial market potential. This expansion aligns well with Safety Shot's existing expertise in rapid-onset wellness formulations, making the transition into cognitive enhancement and sleep aid products a natural progression.

The development approach centers on Safety Shot's philosophy of "over-engineering," suggesting a focus on creating premium, highly effective formulations. The company plans to use ingredients not typically found in most sleep aid products, indicating potential differentiation in a crowded market. However, investors should note that this represents an R&D announcement with prototypes expected later this year, meaning the revenue impact will be delayed.